The global TAVR embolic protection market is experiencing steady growth, with revenue estimated to increase from approximately $124 million in 2023 to around $403 million by 2032. This growth, driven ...

United States Embolic Protection Device Market is expected to reach US$ 650 million by 2033 from US$ 360 million in 2024, with a CAGR of 6.96% from 2025 to 2033. Rising cardiovascular operations, ...

CHICAGO, IL—Cerebral embolic protection devices are infrequently used during transcatheter aortic valve implantation procedures in the United States, and new data suggest their use does not appear to ...

Austin, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Embolic Protection Devices Market Size and Growth Analysis: According to SNS Insider, the global Embolic Protection Devices Market was valued at USD 656.60 ...

Please provide your email address to receive an email when new articles are posted on . Routine cerebral embolic protection did not reduce stroke in patients undergoing transcatheter aortic valve ...

Please provide your email address to receive an email when new articles are posted on . The device (TriGuard 3, Keystone Heart) showed potential to prevent larger ischemic brain lesions, Jeffrey W.

DUBLIN, Oct. 9, 2020 /PRNewswire/ -- The "Embolic Protection Devices Market - Global Outlook and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering. The market is growing ...

Less than a year after debuting its Wirion embolic protection system, Cardiovascular Systems is recalling all of the devices manufactured and distributed between January and November 2021. The Wirion ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

The "Embolic Protection Device Market Report, Forecast by Product, Application, Procedure, Material, Usage, End-User, Countries and Company Analysis, 2024-2032" report has been added to ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...